Celgene win leaves Bass even in PTAB institution game

Managing IP is part of Legal Benchmarking Limited, 1-2 Paris Gardens, London, SE1 8ND

Copyright © Legal Benchmarking Limited and its affiliated companies 2026

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

Cookies Settings

Celgene win leaves Bass even in PTAB institution game

kyle-bass-150.jpg

The PTAB has denied institution of a Coalition for Affordable Drugs inter partes review petition challenging a Celgene patent. This leaves Kyle Bass with a 50% institution success rate in the 14 petitions the Board has decided thus far

The Patent Trial and Appeal Board today released its 14th decision on a Coalition for Affordable Drugs inter partes review, denying a petition challenging a Celgene patent for the Pomalyst myeloma cancer treatment.

It is Celgene’s first good news in its disputes with hedge fund manager Kyle Bass at the PTAB, with trials instituted for four other IPRs challenging its patents. The Board had also rejected its motion to sanction Bass.

The decision also leaves Bass even in terms of institutions and denials so far, with seven petitions instituted (one of which was granted in part) and seven denied. The Coalition for Affordable Drugs, which was set up by Bass and Erich Spangenberg, has filed 33 petitions in total.

The Board should also give a decision this month on an IPR filed on May 21 challenging US Patent 6,926,907, which is owned by Pozen and covers the Vimovo treatment. Horizon Pharma bought the US rights to the stomach ulcer treatment in 2013.

In its latest institution decision, the PTAB said the information presented in the petition and accompanying evidence did not establish a reasonable likelihood that the Coalition for Affordable Drugs would prevail in showing the unpatentability of the challenged claims.

The institution decisions the PTAB has given on the Coalition's petitions so far are below. 

For full details of all petitions filed by the Coalition as well as data on the most-active PTAB petitioners this year, subscribers and trialists can read our "Data: Analysing the busiest PTAB petitioners, patent owners and law firms so far in 2015" article here. 

INSTITUTION DECISIONS ON COALITION FOR AFFORDABLE DRUGS' IPRS 

IPR number

Filed

Law firm used by the Coalition

Patent number

Patent owner

Drug used in

Instituted?

2015-00720

10 Feb

Skiermont Puckett

8,663,685

Acorda Therapeutics

Ampyra

NO

2015-00817

27 Feb

Skiermont Puckett

8,007,826

Acorda Therapeutics

Ampyra

NO

2015-00988

1 Apr

Skiermont Puckett

6,773,720

Cosmo/Nogra/Shire

Lialda

YES

2015-00990

1 Apr

Merchant & Gould

7,056,886

NPS/Shire

Gattex

YES

2015-01018

6 Apr

Merchant & Gould

7,895,059

Jazz Pharmaceuticals

Xyrem

NO

2015-01076

20 Apr

Merchant & Gould

8,754,090

Pharmacyclics

Imbruvica

NO

2015-01086

22 Apr

Neifeld IP Law

8,759,393

Biogen International

Tecfidera

NO

2015-01102

23 Apr

Skiermont Puckett

6,315,720

Celgene Corporation

Revlimid

YES

2015-01096

23 Apr

Skiermont Puckett

6,315,720

Celgene Corporation

Revlimid

YES

2015-01103

23 Apr

Skiermont Puckett

6,315,720

Celgene Corporation

Revlimid

YES

2015-01092

23 Apr

Skiermont Puckett

6,045,501

Celgene Corporation

Pomalyst, Revlimid, Thalomid

YES

2015-01093

23 Apr

Merchant & Gould

7,056,886

NPS/Shire

Gattex

YES (for some claims)

2015-01136

1 May

Neifeld IP Law

8,399,514

Biogen MA

Tecfidera

NO

2015-01169

7 May

Merchant & Gould

5,635,517

Celgene Corporation

Pomalyst

NO

The IPRs list the petitioners as the Coalition for Affordable Drugs, J Kyle Bass, Erich Spangenberg, Hayman Capital Management, various Hayman funds, IP Navigation Group, and nXn Partners

Source: Docket Navigator

more from across site and SHARED ros bottom lb

More from across our site

The firm has taken the bold step of ditching the billable hour as its default pricing mechanism – watch now as rivals follow suit
The IP services provider is targeting further expansion as cost and efficiency pressures push law firms and in-house teams to rethink how they manage global portfolios
Two experienced UPC practitioners join the UK IP boutique’s growing German operation, with further recruitment planned as the firm expands in Europe
The Australian IP firm is taking on bigger rivals in Southeast Asia, betting that agility and transparent pricing can help it stand out
The firm has brought in former Weil IP leaders Doug Lumish and Jeff Homrig as it looks to deepen its patent, trade secrets and ITC bench
Bird & Bird helps GSK score a major injunction as the battle to become the UPC’s busiest division tightens, and overall filings reach a new monthly high
CEO Annette Bach explains how the Danish IP consultancy plans to build on its 65% profit growth while keeping external investment off the table for now
Belgian attorneys have revived fax systems to protect clients’ filing rights, while uncertainty over exposed patent data has left firms struggling to answer questions about the breach
In his first interview since leaving Weil Gotshal & Manges, Chris Henry explains why he returned to Latham and how he plans to bolster its tech disputes offering
As GTA VI underlines the extraordinary value of gaming franchises, lawyers at Clifford Chance say investors need to know the IP behind their next deal can deliver the growth they are paying for
Gift this article